Phase IIa Trial of Metformin for Preventing Oral Cancer in Premalignant Lesions
A phase IIa trial is investigating the efficacy of metformin hydrochloride in preventing oral cancer in patients with premalignant lesions.
Indication
Clinical and regulatory intelligence for Oral Cancer with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.